Chemotherapy and Immunotherapy
Comprehensive Examination ACTUAL
EXAM 2026/2027 | Chemo Immuno
Certification | Verified Q&A | Pass
Guaranteed - A+ Graded
Section 1: Principles of Chemotherapy (12 Questions)
Q1. A 62-year-old male with diffuse large B-cell lymphoma is scheduled for R-CHOP chemotherapy. The
oncologist emphasizes the importance of administering rituximab on day 1 before cyclophosphamide,
doxorubicin, vincristine, and prednisone. Which principle of combination chemotherapy best explains
this sequencing strategy?
A. Rituximab is cell-cycle specific and must be given first to synchronize tumor cells
B. Rituximab depletes B-cells and enhances subsequent chemotherapy efficacy by reducing tumor
burden and improving drug penetration
C. Rituximab is least toxic and should be administered before more toxic agents
D. Rituximab requires acidic pH and must precede agents that alter pH
Correct Answer: B
Rationale: Rituximab, a monoclonal antibody targeting CD20 on B-lymphocytes, functions as a biologic
agent that depletes malignant B-cells through antibody-dependent cellular cytotoxicity (ADCC),
complement-dependent cytotoxicity (CDC), and direct apoptosis. Administering rituximab first reduces
tumor burden, potentially improving vascular access and drug penetration for subsequent cytotoxic
agents (cyclophosphamide, doxorubicin, vincristine). This sequencing exemplifies the combination
chemotherapy principle of using agents with different mechanisms and non-overlapping toxicities to
maximize tumor cell kill across heterogeneous cell populations. (ONS Standard: Combination
Chemotherapy Principles)
,Q2. A 45-year-old female with acute myeloid leukemia (AML) is receiving induction chemotherapy with
cytarabine and daunorubicin (7+3 regimen). On day 5 of treatment, her uric acid rises to 12.4 mg/dL,
potassium to 6.2 mEq/L, phosphorus to 5.8 mg/dL, and calcium drops to 7.1 mg/dL. Which
pathophysiological mechanism best explains this metabolic constellation?
A. Tumor lysis syndrome from rapid malignant cell breakdown releasing intracellular contents
B. Chemotherapy-induced renal tubular acidosis
C. Daunorubicin cardiotoxicity causing hypoperfusion and lactic acidosis
D. Cytarabine neurotoxicity affecting hypothalamic regulation
Correct Answer: A
Rationale: Tumor lysis syndrome (TLS) is an oncologic emergency caused by massive tumor cell lysis,
either spontaneously or following cytotoxic chemotherapy, releasing intracellular potassium,
phosphorus, and nucleic acids (metabolized to uric acid) into the circulation. The characteristic
metabolic triad—hyperuricemia, hyperkalemia, hyperphosphatemia with secondary hypocalcemia (from
calcium-phosphate precipitation)—reflects the intracellular composition of rapidly dividing malignant
cells. High-grade AML and aggressive lymphomas carry the highest TLS risk. Prophylaxis with aggressive
hydration, allopurinol or rasburicase, and electrolyte monitoring is essential per NCCN guidelines. (NCCN
Guideline: Tumor Lysis Syndrome Management)
Q3. A 58-year-old female receiving doxorubicin for breast cancer reports pain, burning, and erythema at
the IV site during infusion. The nurse stops the infusion and notes swelling and induration. Which
immediate intervention is most appropriate for an anthracycline extravasation?
A. Apply warm compresses and elevate the extremity
B. Aspirate any residual drug, remove the catheter, and administer dexrazoxane subcutaneously around
the extravasation site within 6 hours
C. Flush the line with normal saline to dilute the drug
D. Apply cold compresses and inject hyaluronidase
Correct Answer: B
Rationale: Anthracycline extravasation requires immediate cessation of infusion, aspiration of residual
drug from the catheter and tissues, catheter removal, and administration of dexrazoxane (Totect), a
topoisomerase II catalytic inhibitor that chelates iron and prevents anthracycline-mediated free radical
generation and tissue necrosis. Dexrazoxane must be administered intravenously (not subcutaneously)
in a distant vein within 6 hours of extravasation for three consecutive days. This intervention is critical to
prevent progressive tissue destruction, ulceration, and necrosis that can require surgical debridement.
(ONS Standard: Extravasation Management; NIOSH 2026 Hazardous Drug Handling)
,Q4. A 70-year-old male with metastatic colorectal cancer is receiving FOLFOX (folinic acid, fluorouracil,
oxaliplatin). He reports acute numbness and tingling in his hands and throat when drinking cold
beverages. Which pathophysiological mechanism best explains this acute neurotoxicity?
A. Demyelination of peripheral nerves from chronic cumulative platinum exposure
B. Oxaliplatin metabolite oxalate chelating calcium and altering voltage-gated sodium channel kinetics
C. Direct axonal degeneration from platinum-DNA adduct accumulation
D. Autoimmune ganglionitis triggered by platinum compounds
Correct Answer: B
Rationale: Acute oxaliplatin-induced neurotoxicity (cold-induced dysesthesia, paresthesias) results from
the formation of oxalate, a metabolite of oxaliplatin, which chelates extracellular calcium ions. This
calcium chelation alters the kinetics of voltage-gated sodium channels in peripheral sensory neurons,
lowering the threshold for depolarization and causing transient, cold-exacerbated paresthesias. This
mechanism is reversible and distinct from chronic cumulative sensory neuropathy (length-dependent
axonal degeneration) that occurs with higher cumulative doses (>850–1,000 mg/m²). Patient education
to avoid cold exposure during and for several days after infusion is essential. (ONS Standard:
Neurotoxicity Management)
Q5. A 55-year-old female with ovarian cancer is receiving carboplatin AUC 6. Her baseline creatinine is
1.2 mg/dL, but on the day of chemotherapy, it has risen to 1.8 mg/dL. Which pharmacokinetic principle
necessitates dose adjustment?
A. Carboplatin is hepatically metabolized and requires dose reduction for elevated bilirubin
B. Carboplatin is renally cleared; elevated creatinine reduces drug elimination, increasing exposure and
toxicity risk
C. Carboplatin is protein-bound and requires adjustment for low albumin
D. Carboplatin is metabolized by CYP3A4 and interacts with renal function
Correct Answer: B
Rationale: Carboplatin is primarily eliminated unchanged by glomerular filtration, with renal clearance
accounting for approximately 60–70% of total drug clearance. The Calvert formula (Dose = Target AUC ×
[GFR + 25]) directly incorporates glomerular filtration rate for dosing, making renal function the primary
determinant of drug exposure. An acute rise in creatinine from 1.2 to 1.8 mg/dL indicates reduced GFR,
which would increase carboplatin exposure (higher AUC), intensifying myelosuppression (particularly
thrombocytopenia) without therapeutic benefit. Dose recalculation using updated renal function is
mandatory before administration. (ONS Standard: Renal Dosing Principles)
, Q6. A 48-year-old male with testicular cancer receiving bleomycin, etoposide, and cisplatin (BEP
regimen) develops dyspnea, dry cough, and bilateral crackles on day 12 of cycle 2. Chest X-ray shows
diffuse interstitial infiltrates. Which cumulative dose threshold most significantly increases his risk for
this potentially fatal toxicity?
A. >100 units of bleomycin
B. >200 units of bleomycin
C. >400 units of bleomycin
D. >600 units of bleomycin
Correct Answer: C
Rationale: Bleomycin-induced pulmonary toxicity, including interstitial pneumonitis and pulmonary
fibrosis, is dose-dependent with significantly increased risk at cumulative doses exceeding 400 units (400
mg). The pathophysiology involves bleomycin-mediated endothelial and epithelial cell damage through
free radical generation, inflammatory cell infiltration, and fibroblast activation leading to collagen
deposition. Risk factors include advanced age, renal dysfunction (reduced bleomycin clearance),
concurrent oxygen therapy (which potentiates free radical injury), and prior thoracic radiation.
Pulmonary function tests (DLCO monitoring) and early recognition of subclinical decline are essential for
toxicity prevention. (NCCN Guideline: Bleomycin Pulmonary Toxicity Monitoring)
Q7. A 65-year-old female with HER2-positive breast cancer is receiving trastuzumab in combination with
paclitaxel. Which principle explains why trastuzumab is classified as a targeted therapy rather than
traditional chemotherapy?
A. Trastuzumab is cell-cycle specific and targets dividing cells only
B. Trastuzumab binds to the HER2 receptor, blocking downstream signaling and mediating immune-
mediated cytotoxicity without direct DNA damage
C. Trastuzumab is administered orally and therefore not classified as chemotherapy
D. Trastuzumab causes less nausea than traditional chemotherapy
Correct Answer: B
Rationale: Trastuzumab is a humanized monoclonal antibody that specifically binds to the extracellular
domain of HER2 (human epidermal growth factor receptor 2), a tyrosine kinase receptor overexpressed
in 15–20% of breast cancers. Its mechanism involves (1) blockade of ligand-independent HER2
dimerization and downstream PI3K/Akt and MAPK signaling pathways inhibiting proliferation and
survival; (2) antibody-dependent cellular cytotoxicity (ADCC) recruiting NK cells; and (3) inhibition of
metalloproteinase-mediated receptor shedding. Unlike cytotoxic chemotherapy, trastuzumab does not
directly damage DNA or interfere with microtubule function, resulting in a distinct toxicity profile
(cardiotoxicity rather than myelosuppression). (ONS Standard: Targeted Therapy Classification)
Comprehensive Examination ACTUAL
EXAM 2026/2027 | Chemo Immuno
Certification | Verified Q&A | Pass
Guaranteed - A+ Graded
Section 1: Principles of Chemotherapy (12 Questions)
Q1. A 62-year-old male with diffuse large B-cell lymphoma is scheduled for R-CHOP chemotherapy. The
oncologist emphasizes the importance of administering rituximab on day 1 before cyclophosphamide,
doxorubicin, vincristine, and prednisone. Which principle of combination chemotherapy best explains
this sequencing strategy?
A. Rituximab is cell-cycle specific and must be given first to synchronize tumor cells
B. Rituximab depletes B-cells and enhances subsequent chemotherapy efficacy by reducing tumor
burden and improving drug penetration
C. Rituximab is least toxic and should be administered before more toxic agents
D. Rituximab requires acidic pH and must precede agents that alter pH
Correct Answer: B
Rationale: Rituximab, a monoclonal antibody targeting CD20 on B-lymphocytes, functions as a biologic
agent that depletes malignant B-cells through antibody-dependent cellular cytotoxicity (ADCC),
complement-dependent cytotoxicity (CDC), and direct apoptosis. Administering rituximab first reduces
tumor burden, potentially improving vascular access and drug penetration for subsequent cytotoxic
agents (cyclophosphamide, doxorubicin, vincristine). This sequencing exemplifies the combination
chemotherapy principle of using agents with different mechanisms and non-overlapping toxicities to
maximize tumor cell kill across heterogeneous cell populations. (ONS Standard: Combination
Chemotherapy Principles)
,Q2. A 45-year-old female with acute myeloid leukemia (AML) is receiving induction chemotherapy with
cytarabine and daunorubicin (7+3 regimen). On day 5 of treatment, her uric acid rises to 12.4 mg/dL,
potassium to 6.2 mEq/L, phosphorus to 5.8 mg/dL, and calcium drops to 7.1 mg/dL. Which
pathophysiological mechanism best explains this metabolic constellation?
A. Tumor lysis syndrome from rapid malignant cell breakdown releasing intracellular contents
B. Chemotherapy-induced renal tubular acidosis
C. Daunorubicin cardiotoxicity causing hypoperfusion and lactic acidosis
D. Cytarabine neurotoxicity affecting hypothalamic regulation
Correct Answer: A
Rationale: Tumor lysis syndrome (TLS) is an oncologic emergency caused by massive tumor cell lysis,
either spontaneously or following cytotoxic chemotherapy, releasing intracellular potassium,
phosphorus, and nucleic acids (metabolized to uric acid) into the circulation. The characteristic
metabolic triad—hyperuricemia, hyperkalemia, hyperphosphatemia with secondary hypocalcemia (from
calcium-phosphate precipitation)—reflects the intracellular composition of rapidly dividing malignant
cells. High-grade AML and aggressive lymphomas carry the highest TLS risk. Prophylaxis with aggressive
hydration, allopurinol or rasburicase, and electrolyte monitoring is essential per NCCN guidelines. (NCCN
Guideline: Tumor Lysis Syndrome Management)
Q3. A 58-year-old female receiving doxorubicin for breast cancer reports pain, burning, and erythema at
the IV site during infusion. The nurse stops the infusion and notes swelling and induration. Which
immediate intervention is most appropriate for an anthracycline extravasation?
A. Apply warm compresses and elevate the extremity
B. Aspirate any residual drug, remove the catheter, and administer dexrazoxane subcutaneously around
the extravasation site within 6 hours
C. Flush the line with normal saline to dilute the drug
D. Apply cold compresses and inject hyaluronidase
Correct Answer: B
Rationale: Anthracycline extravasation requires immediate cessation of infusion, aspiration of residual
drug from the catheter and tissues, catheter removal, and administration of dexrazoxane (Totect), a
topoisomerase II catalytic inhibitor that chelates iron and prevents anthracycline-mediated free radical
generation and tissue necrosis. Dexrazoxane must be administered intravenously (not subcutaneously)
in a distant vein within 6 hours of extravasation for three consecutive days. This intervention is critical to
prevent progressive tissue destruction, ulceration, and necrosis that can require surgical debridement.
(ONS Standard: Extravasation Management; NIOSH 2026 Hazardous Drug Handling)
,Q4. A 70-year-old male with metastatic colorectal cancer is receiving FOLFOX (folinic acid, fluorouracil,
oxaliplatin). He reports acute numbness and tingling in his hands and throat when drinking cold
beverages. Which pathophysiological mechanism best explains this acute neurotoxicity?
A. Demyelination of peripheral nerves from chronic cumulative platinum exposure
B. Oxaliplatin metabolite oxalate chelating calcium and altering voltage-gated sodium channel kinetics
C. Direct axonal degeneration from platinum-DNA adduct accumulation
D. Autoimmune ganglionitis triggered by platinum compounds
Correct Answer: B
Rationale: Acute oxaliplatin-induced neurotoxicity (cold-induced dysesthesia, paresthesias) results from
the formation of oxalate, a metabolite of oxaliplatin, which chelates extracellular calcium ions. This
calcium chelation alters the kinetics of voltage-gated sodium channels in peripheral sensory neurons,
lowering the threshold for depolarization and causing transient, cold-exacerbated paresthesias. This
mechanism is reversible and distinct from chronic cumulative sensory neuropathy (length-dependent
axonal degeneration) that occurs with higher cumulative doses (>850–1,000 mg/m²). Patient education
to avoid cold exposure during and for several days after infusion is essential. (ONS Standard:
Neurotoxicity Management)
Q5. A 55-year-old female with ovarian cancer is receiving carboplatin AUC 6. Her baseline creatinine is
1.2 mg/dL, but on the day of chemotherapy, it has risen to 1.8 mg/dL. Which pharmacokinetic principle
necessitates dose adjustment?
A. Carboplatin is hepatically metabolized and requires dose reduction for elevated bilirubin
B. Carboplatin is renally cleared; elevated creatinine reduces drug elimination, increasing exposure and
toxicity risk
C. Carboplatin is protein-bound and requires adjustment for low albumin
D. Carboplatin is metabolized by CYP3A4 and interacts with renal function
Correct Answer: B
Rationale: Carboplatin is primarily eliminated unchanged by glomerular filtration, with renal clearance
accounting for approximately 60–70% of total drug clearance. The Calvert formula (Dose = Target AUC ×
[GFR + 25]) directly incorporates glomerular filtration rate for dosing, making renal function the primary
determinant of drug exposure. An acute rise in creatinine from 1.2 to 1.8 mg/dL indicates reduced GFR,
which would increase carboplatin exposure (higher AUC), intensifying myelosuppression (particularly
thrombocytopenia) without therapeutic benefit. Dose recalculation using updated renal function is
mandatory before administration. (ONS Standard: Renal Dosing Principles)
, Q6. A 48-year-old male with testicular cancer receiving bleomycin, etoposide, and cisplatin (BEP
regimen) develops dyspnea, dry cough, and bilateral crackles on day 12 of cycle 2. Chest X-ray shows
diffuse interstitial infiltrates. Which cumulative dose threshold most significantly increases his risk for
this potentially fatal toxicity?
A. >100 units of bleomycin
B. >200 units of bleomycin
C. >400 units of bleomycin
D. >600 units of bleomycin
Correct Answer: C
Rationale: Bleomycin-induced pulmonary toxicity, including interstitial pneumonitis and pulmonary
fibrosis, is dose-dependent with significantly increased risk at cumulative doses exceeding 400 units (400
mg). The pathophysiology involves bleomycin-mediated endothelial and epithelial cell damage through
free radical generation, inflammatory cell infiltration, and fibroblast activation leading to collagen
deposition. Risk factors include advanced age, renal dysfunction (reduced bleomycin clearance),
concurrent oxygen therapy (which potentiates free radical injury), and prior thoracic radiation.
Pulmonary function tests (DLCO monitoring) and early recognition of subclinical decline are essential for
toxicity prevention. (NCCN Guideline: Bleomycin Pulmonary Toxicity Monitoring)
Q7. A 65-year-old female with HER2-positive breast cancer is receiving trastuzumab in combination with
paclitaxel. Which principle explains why trastuzumab is classified as a targeted therapy rather than
traditional chemotherapy?
A. Trastuzumab is cell-cycle specific and targets dividing cells only
B. Trastuzumab binds to the HER2 receptor, blocking downstream signaling and mediating immune-
mediated cytotoxicity without direct DNA damage
C. Trastuzumab is administered orally and therefore not classified as chemotherapy
D. Trastuzumab causes less nausea than traditional chemotherapy
Correct Answer: B
Rationale: Trastuzumab is a humanized monoclonal antibody that specifically binds to the extracellular
domain of HER2 (human epidermal growth factor receptor 2), a tyrosine kinase receptor overexpressed
in 15–20% of breast cancers. Its mechanism involves (1) blockade of ligand-independent HER2
dimerization and downstream PI3K/Akt and MAPK signaling pathways inhibiting proliferation and
survival; (2) antibody-dependent cellular cytotoxicity (ADCC) recruiting NK cells; and (3) inhibition of
metalloproteinase-mediated receptor shedding. Unlike cytotoxic chemotherapy, trastuzumab does not
directly damage DNA or interfere with microtubule function, resulting in a distinct toxicity profile
(cardiotoxicity rather than myelosuppression). (ONS Standard: Targeted Therapy Classification)
